Multicenter phase 1-2 study of vistusertib plus anastrazole for HR-positive recurrent or metastatic endometrial cancer

Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors. The PI3K-AKT-mTOR pathway deregulation observed in endometrial cancer drives hormonal resistance, thus supporting the rationale of combining mTOR inhibitor with endocrine therapy. The multicenter phase 1-2 VICTORIA study in France randomized patients with HR-positive recurrent or metastatic endometrial cancer to the mTOR-inhibitor vistusertib plus anastrozole (V+A) or anastrozole alone (A). The 8-week progression-free rate was 67.3% in the V+A group versus 39.1% in the A group. The median PFS was 5.2 months in the V+A group versus 1.9 months in the A group. The authors conclude that adding vistusertib to anastrozole improved outcomes for patients with R/M endometrial cancer, with manageable adverse events (visual abstract).